ArticleMacromolecular rapid communications2026
Ex Vivo Evaluation of Poly(Solketal Acrylate) Nanoparticles for Intravitreal Drug Delivery to the Posterior Eye Segment.
Article in Macromolecular rapid communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Owing the complex anatomy and multiple physiological barriers, delivering drugs to the posterior segment of the eye remains challenging. While intravitreal injection can improve drug delivery, the diffusion of therapeutics through the vitreous humor and their uptake by the retina remain limited due to the anionic nature of the vitreous humor, attributed to its collagen and glycosaminoglycan content. Poly(solketal acrylate)-based nanoparticles (PSA-NPs) were developed via single-emulsion solvent evaporation and nanoprecipitation techniques and loaded with Nile red (NR-PSA-NPs) as a hydrophobic drug model, enabling in vitro and ex vivo tracking via fluorescence microscopy. These NPs exhibit a neutral to negative surface charge, enhancing their distribution through the vitreous humor. Evaluating these NPs for drug delivery, cytotoxicity studies using retinal cells confirmed their excellent nontoxic profiles. Additionally, fluorescence microscopy and FACS analysis revealed a significant increase in the uptake of NR-PSA-NPs in ARPE-19 cells (human retinal pigment epithelial cell line) compared to that of free dye. Moreover, incubation of NR-PSA-NPs with retinal organ cultures and their intravitreal injection into whole porcine eyes showed red fluorescence across all retinal layers, confirming successful uptake, distribution, and widespread retinal penetration, making these NPs promising carriers for delivering hydrophobic drugs to the posterior eye segment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.